Your gift is 100% tax deductible
Español
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Your gift enables us to support people with cancer and fund research breakthroughs.
The amount must be greater than or equal to $5
Your gift is 100% tax deductible
Important research into multiple myeloma is being done in university hospitals, medical centers, and other institutions around the world. Each year, scientists find out more about what causes the disease, how to better diagnose and classify it, and how to improve treatment.
Researchers are constantly learning more about the changes in the genes and proteins inside myeloma cells that help them grow. Knowing about these types of changes is helping them design better medicines to treat myeloma. It's also helping doctors figure out which myelomas are at higher risk for progressing. This could affect which treatments a person should get.
Researchers have also found that bone marrow support tissues and bone cells make growth factors that can help myeloma cells grow. In turn, the myeloma cells make substances that cause bone cells to undergo changes that weaken the bones. These discoveries are helping researchers develop new drugs to block these growth factors, slow down the cancer, and reduce bone destruction.
Even though smoldering multiple myeloma (SMM) usually has a low risk of turning into active myeloma right away, in some people the SMM has features that put it at higher risk of developing into active myeloma.
Doctors are looking to better define which features of SMM make this more likely. Treating people whose SMM has these features, rather than waiting until symptoms appear, may help delay the progression to active myeloma, and it may also improve survival. This is an active area of research.
There's been a great deal of progress in multiple myeloma treatment in recent years. While myeloma is still very hard to cure, many newer types of medicines have become available, which have greatly extended the length of time most people live with this disease.
Doctors are now trying to determine how best to combine these medicines, which order to use them in, and which ones might be more helpful for people whose myeloma has certain features (such as certain gene or chromosome changes).
For example, newer treatments such as bispecific T-cell engagers (BiTEs) and CAR T-cell therapy, which help the person's immune system find and attack the cancer cells, are now available. Most often, these are used later in the course of treatment, after other medicines have been tried. But doctors are now studying if using them earlier might be more helpful.
As researchers learn more about the gene and protein changes inside myeloma cells that help them grow, they are developing newer types of medicines to treat myeloma as well. Many of these are now being studied in clinical trials.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
Laubach JP. Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/multiple-myeloma-clinical-features-laboratory-manifestations-and-diagnosis on August 20, 2024.
Laubach JP. Multiple myeloma: Overview of Management. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/multiple-myeloma-overview-of-management on August 20, 2024.
Laubach JP. Multiple myeloma: Treatment of second or later relapse. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/multiple-myeloma-treatment-of-second-or-later-relapse on August 20, 2024.
Mateos V-M. Smoldering multiple myeloma. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/smoldering-multiple-myeloma on August 20, 2024.
National Cancer Institute. Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version. 2024. Accessed at https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq on August 20, 2024.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Multiple myeloma. V.4.2024. Accessed at www.nccn.org on August 20, 2024.
Rajkumar SV, Dispenzieri A. Chapter 101: Multiple myeloma and related disorders. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. Abeloff’s Clinical Oncology. 6th edition. Philadelphia, PA. Elsevier: 2020.
Last Revised: August 27, 2024
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
We fund research breakthroughs that save lives. Your year-end gift helps find new treatments for cancer.